Magnetic resonance imaging method and compounds for use in the method
AssigneeGe Healthcare Limited
InventorsPål Rongved, Jan Karlsson, Karen Saebo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia and to compounds for use as MR contrast agents in the method.
Claims23
Method of MR imaging to identify diseased areas comprising areas suffering from myocardial ischemia, said method comprising
- a) administering to a human or non-human animal body a contrast agent comprising
- (i) at least one complex comprising a Mn2+ ion and a complexing moiety wherein said complex has a thermodynamic formation constant between 103 and 1016 and wherein said complex shows a dissociation of greater than 50% and a half-life of less than 1 min under physiological conditions;
- and
- (ii) 0 to 2 mol Ca2+ per mol Mn2+;
- b) exposing said body to a regime of physical and/or pharmacological stress before or simultaneously to the contrast agent administration;
- c) collecting MR imaging data and;
- d) optionally providing MR images of an area of interest.
11-12. (canceled)
Mixture comprising a complex having a thermodynamic formation constant between 103 and 1016 which comprises Mn2+ and a complexing moiety, wherein said complex shows a dissociation of greater than 50% and a half-life of less than 1 min under physiologic conditions and 0.1 to 2 mol Ca2+ per mol Mn2+ for the manufacture of a contrast agent for use in MR imaging of the myocardium, preferably for use in the MR imaging detection of myocardial ischemia and infarction.
16-18. (canceled)
Compounds of the formula (I)
- Mnm (P3O105−)nZo (I),
- wherein m, n, and o are positive integers from 1 and 10 and Z is hydrogen or a pharmaceutical acceptable counterion for use in a MR contrast agent.
Dependencies are inferred from the claim text.